Navigation Links
Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology
Date:4/23/2009

tiated mature cells, such as adult skin cells, to become pluripotent or stem-cell like and do not rely on the use of stem cells derived from embryos. Because iPS cells can differentiate into any cell type, iPS cells are considered of great importance to medicine because they can be used to model human diseases, discover and test drug candidates and develop personalized cell therapies. Previously, iPS cell generation required the delivery of genetic material through viruses or plasmids, which carry risks from insertion and are time-consuming, inefficient methods. Now, in collaboration with Dr. Ding, Fate Therapeutics and Stemgent have developed small molecules and proteins for the safe and efficient creation of high quality iPS cells that can reproducibly differentiate into essential cell types for drug discovery and development.

"Catalyst's technology - creating and differentiating iPS cells into distinct cell types - will uncover the essential epigenetic and gene expression profiles associated with the derivation of specific cell lineages," said Mr. Grayson. "These same technologies will prove critical in our discovery and development of conventional pharmaceuticals to guide cell fate for therapeutic benefit."

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating stem cell biology to develop therapeutics based on modulating cell fate and to enable a new drug discovery paradigm with the Company's proprietary induced-pluripotent stem (iPS) cell technology. The Company's first therapeutic candidate is scheduled to enter clinical trials in early 2009 in hematopoietic reconstitution. Fate Therapeutics is a private biotech company headquartered in La Jolla, CA. For more information, please visit http://www.fatetherapeutics.com.

About Stemgent, Inc.

'/>"/>
SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... create a highly sensitive chemical sensor based on the ... electronic properties that the researchers were able to exploit ... times. , The study is available online in advance ... Salehi- Khojin, asst professor of mechanical and industrial engineering ... Bijandra Kumar, post doc where they are doing research ...
(Date:9/22/2014)... , Sept. 22, 2014 US demand ... demand for specialty biocides is forecast to rise 3.9 ... volume terms, demand is projected to increase 1.3 percent ... period. A strong rebound in construction expenditures will support ... and coatings markets, while growth in consumer spending and ...
(Date:9/22/2014)... 2014 Follow us on ... young has groomed and nurtured anti-aging products and ... emphasis on appearance maintenance is benefitting the market ... protein obtained from the bacterium, Clostridium Botulinum, which ... relaxation. With cosmetic indications for botulinum toxin ranging ...
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 ... announced that it has entered into a collaboration ... UHN,s Centre for Molecular Design and Preformulations (CMDP) ... The goal of the project is to increase ... proprietary buccal insulin spray product, thereby reducing the ...
Breaking Biology Technology:Graphene imperfections key to creating hypersensitive 'electronic nose' 2US Biocides Market 2US Biocides Market 3Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 2Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 3Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4
... Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/,-- Curis, ... development company focused on,developing proprietary targeted medicines for ... companies with a focus on the development of,prescription ... that they,have entered into a worldwide, exclusive license ...
... China, Aug. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical company producing ... announced the appointment of Mr.,William Wei Lee as an ... effective August 4, 2009. Mr. Jiang Qi-Feng resigned from ...
... 6 Interleukin Genetics, Inc. (NYSE Amex: ... conference call and webcast on Thursday, August 13, 2009, at 4:30 ... financial results. , , To access the live ... replay access of the teleconference will be available on the Investors ...
Cached Biology Technology:Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 2Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 3Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 4Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 5Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 6China Sky One Medical, Inc. Appoints New Independent Director 2China Sky One Medical, Inc. Appoints New Independent Director 3
(Date:9/22/2014)... (Sept. 22, 2014) As genetic sequencing technologies continue ... is a critical need to establish appropriate policies and ... experts have said. A special policy issue of the ... online today and edited by experts with the Center ... of Medicine gives policy makers the tools to jumpstart ...
(Date:9/22/2014)... fishes that manufacture their own "antifreeze" proteins to ... an unfortunate side effect, researchers report: The protein-bound ... melting even when temperatures warm. , The ... the National Academy of Sciences . , "We ... of the evolution of antifreeze proteins in Antarctic ...
(Date:9/22/2014)... of the fires captured in this image burn in Khabarovsk ... Okhotsk. Dozens of red hotspots, accompanied by plumes of smoke ... grey, blows to the east towards the Sea of Okhotsk. ... of this area, swampy forest inhabit the central depression, and ... While large wildfires are common in Russia in the summer, ...
Breaking Biology News(10 mins):Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... Bread wheat ( Triticum aestivum ) is one of ... the calories consumed by people. Fully 35% of the world,s ... Now an international team of scientists, including a group from ... analysis of its full genome. The study reveals ...
... pro-iBiosphere aims to prepare (= pro), through ... (= sphere) for intelligent (= i) management of biodiversity ... Open Biodiversity Knowledge Management System will play a major ... It will create an authoritative framework including discovery of ...
... published by the U.S. Department of Agriculture,s (USDA) Economic ... the journal Science examine the relationship between ... and their importance in agricultural input industries. The ... study that provides new details on the rapid growth ...
Cached Biology News:Bread wheat's large and complex genome is revealed 2Bread wheat's large and complex genome is revealed 3Toward an European open biodiversity knowledge management system 2USDA study shows trends in public and private agricultural R&D 2
... is an integrated digital microscope and camera ... equipment setup, optical adjustment or software installation. ... technology, COOLSCOPE combines simplicity and advanced technology ... offers simultaneous viewing of a macro image ...
... DASGIP Overhead Drive for individual and parallel ... flexible agitation of DASGIP vessels, featuring range ... ,Up to 16 overhead drives can ... Cultivation Systems fedbatch-pro® and cellferm-pro® for microbiology ...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
Biology Products: